Selective Depletion of Tumor‐Infiltrating CD4 + CCR8 + Tregs by AZ084, a Novel CCR8 Antagonist
Cancer Science · 2026
DOI: 10.1111/cas.70465 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, 2026. Verfasst von Yepeng Mao und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China. Hauptthemen laut MEDLINE: T-Lymphocytes, Regulatory, Lymphocytes, Tumor-Infiltrating, Ovarian Neoplasms, Receptors, CCR8. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Jiangsu Province, Natural Science Foundation of Jiangsu Province for Young Scholars.
Abstract (Originalsprache)
Regulatory T cells (Tregs) are key mediators of immunosuppression in ovarian cancer, yet strategies for selectively targeting tumor‐infiltrating Tregs remain limited. CD4 + CCR8 + Tregs have been proposed as a highly suppressive subset, but their functional relevance and therapeutic potential require further investigation. Here, we demonstrate that CCR8 is preferentially expressed on tumor‐infiltrating CD4 + Tregs in syngeneic ID8 and B16 tumor models, accounting for a significantly higher proportion compared with CD4 + conventional T cells and CD8 + T cells ( p < 0.001). Functionally, CD4 + CCR8 + Tregs exhibited enhanced suppressive activity, markedly inhibiting IFN‐γ production by CD8 + T cells ( p < 0.01). The antagonist AZ084 significantly impaired Treg differentiation and alleviated Treg‐mediated suppression in vitro ( p < 0.01). In vivo, AZ084 treatment effectively suppressed tumor growth in both ovarian cancer and melanoma models ( p < 0.01), accompanied by a reduction in tumor‐infiltrating CD4 + CCR8 + Tregs and an increase in CD8 + T cell infiltration and effector function ( p < 0.05). Importantly, AZ084 had minimal impact on splenic immune cell composition ( p > 0.05), suggesting limited systemic immunotoxicity. Collectively, our findings identify CCR8 as a selective marker and functional regulator of tumor‐infiltrating Tregs. Targeting CCR8 with AZ084 represents a promising strategy to enhance antitumor immunity while preserving peripheral immune homeostasis, providing a potential therapeutic approach for ovarian cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
- Branch of National Clinical Research Center for Laboratory Medicine, Nanjing, China.
- Department of Gynecology, The Affiliated Obstetrics and Gynaecology Hospital of Nanjing Medical University, Nanjing, China.
- Department of Clinical Laboratory, Baoshan People's Hospital, Baoshan, China.
ORCID-Profile: Yepeng Mao, Shuna Liu
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Jiangsu Province
- Natural Science Foundation of Jiangsu Province for Young Scholars
Zitieren
APA
Mao, Y., Tao, Z., Liu, S., Liu, Z., Zhang, Y., Zhou, L., Yan, L., Wang, T., Shang, W., Lou, J., Huang, X., Fu, X., & Wang, F. (2026). Selective Depletion of Tumor‐Infiltrating CD4 + CCR8 + Tregs by AZ084, a Novel CCR8 Antagonist. Cancer Science. https://doi.org/10.1111/cas.70465
Vancouver
Mao Y, Tao Z, Liu S, Liu Z, Zhang Y, Zhou L, et al. Selective Depletion of Tumor‐Infiltrating CD4 + CCR8 + Tregs by AZ084, a Novel CCR8 Antagonist. Cancer Science. 2026. doi:10.1111/cas.70465
BibTeX
@article{Mao2026,
author = {Mao, Yepeng and Tao, Ziqi and Liu, Shuna and Liu, Zhijie and Zhang, Yuelu and Zhou, Lingfei and Yan, Lina and Wang, Ting and Shang, Wenwen and Lou, Jianfang and Huang, Xi and Fu, Xin and Wang, Fang},
title = {Selective Depletion of Tumor‐Infiltrating CD4 + CCR8 + Tregs by AZ084, a Novel CCR8 Antagonist},
journal = {Cancer Science},
year = {2026},
doi = {10.1111/cas.70465}
}
EUVIMED